Browse Pediatrics | Stanford Profiles

Current Research and Scholarly InterestsMy laboratory's expertise in cardiovascular phenotyping has led to the development of mouse models of congenital heart disease that recapitulate abnormal loading conditions on the heart. We have used these models to advance our understanding of the mechanisms of right heart failure in children and adults with congenital heart disease with the long term goal of identifying noninvasive diagnostic tools to better assess right ventricular health and to develop right ventricle specific therapeutics.

Shobha Regmi

Research Scientist, Pediatrics - Gastroenterology

BioDr. Regmi earned her PhD in Pharmacy from Yeungnam University, South Korea. Before joining us, she was a postdoctoral fellow in the Department of Radiology under the mentorship of Dr. Avnesh S. Thakor. With over a decade of experience researching novel therapies for inflammatory diseases and expertise in cell therapy, Dr. Regmi brings valuable skills in in vivo and in vitro experimental biology, immunology, complex multicolor flow cytometry, and scientific writing. Her expertise will be instrumental in advancing the Rosen Lab’s research on the molecular mechanisms underlying pediatric IBD and treatment response.
Dr. Regmi’s work will focus on investigating the role of stromal-immune crosstalk that drives ulcerative colitis.

David Rehkopf

Director, Stanford Center on Longevity, Professor of Epidemiology and Population Health, of Sociology, of Medicine (Primary Care and Population Health) and, by courtesy, of Pediatrics, and of Health Policy

BioI am a social epidemiologist and Professor in the Department of Epidemiology and Population Health, the Department of Sociology, and the Division of Primary Care and Population Health in the Department of Medicine. I joined the Stanford University faculty in 2011.

My research examines the health implications of the myriad decisions made every day by corporations and governments—decisions that profoundly shape the social and economic worlds in which we live and work. Although these changes are often invisible in daily life, seemingly minor actions and decisions can serve as structural nudges that produce better or worse health at the population level. My work documents the health consequences of corporate and governmental decisions, providing evidence that can help the public and policymakers develop new strategies to promote health and well-being. Across this work, I focus particularly on the implications of these exposures for health inequalities.

Because policy and programmatic changes can take decades to influence health, my research also includes more basic work to identify biological signals that may serve as early warning signs of systemic disease, particularly accelerated aging. I examine how social and economic policy changes affect a range of early markers of disease and aging, with a recent focus on DNA methylation. I am supported by several grants from the National Institute on Aging and the National Institute on Minority Health and Health Disparities to develop more sensitive approaches for understanding the health effects of social and economic policy changes.

Contact Info

Web page:

http://web.stanford.edu/people/drehkopf

Jenna Reisler

Fellow in Peds/Clinical Informatics

BioJenna Reisler, MD is an Internal Medicine-trained Clinical Informatics Fellow passionate about designing clinical decision support tools that reduce clinician burden and improve patient outcomes. Her work spans CDS for falls prevention, human-centered EHR workflow design, and quality improvement in ambulatory care and inpatient settings. Recent projects include a co-investigator role on an EPIC-based falls prevention CDS tool published in Applied Clinical Informatics, and co-PI of an ACGME Back to Bedside–funded home visit program integrating social determinants of health into residency training.

Jonathan David Reiss

Instructor, Pediatrics - Neonatology

David A. Relman

Thomas C. and Joan M. Merigan Professor and Professor of Microbiology and Immunology

Current Research and Scholarly InterestsMy investigative program focuses on human-microbe interactions and human microbial ecology, and primarily concerns the ecology of human indigenous microbial communities; a secondary interest concerns the classification of humans with systemic infectious diseases, based on features of genome-wide gene transcript abundance patterns and pther aspects of the host response.

Chloe Reuter

Clinical Associate Professor, Medicine - Cardiovascular Medicine
Clinical Associate Professor, Pediatrics - Medical Genetics

BioChloe Reuter is a Genetic Counselor and Clinical Associate Professor in the Division of Cardiovascular Medicine at Stanford University School of Medicine. She is Principal Investigator of an NIH-funded research program focused on developing frameworks for the clinical translation of multi-omic technologies in rare diseases.

Ms. Reuter provides genetic counseling care at the Stanford Center for Inherited Cardiovascular Diseases, specializing in inherited cardiovascular conditions including cardiomyopathies, arrhythmia syndromes, and sudden cardiac death. She has expertise in interpreting complex genomic results from multi-gene panels, exome sequencing, and whole genome sequencing for patients with rare and undiagnosed diseases.

Ms. Reuter's research centers on translating cutting-edge genomic technologies into clinical practice. She develops frameworks for integrating multi-omic data (genomic, transcriptomic, and other omics) into diagnostic workflows and contributes to evidence-based guidelines for variant interpretation and clinical curation. Her work addresses the ethical and practical challenges of implementing these technologies, with particular focus on patient engagement, equitable access to precision medicine, and protocols for returning complex research results. She also conducts genetic counseling practice research, examining patient experiences, psychosocial assessment tools, and healthcare delivery models including telehealth services.

She has contributed to multiple national genomics initiatives including the Undiagnosed Diseases Network and the GREGoR Consortium, applying comprehensive genomic approaches to solve medical mysteries and improve diagnostic outcomes for patients with rare diseases.